Clearmind Medicine Submits Three Patent Applications for Psychedelic Drugs

Patent applications cover combinations of LSD, psilocybin, DMT and SciSparc's Palmitoylethanolamide

Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, said Feb. 21 it has submitted three patent applications under the international Patent Cooperation Treaty. This submission is part of Clearmind’s collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company focused on central nervous system disorder therapies.

The patent applications cover combinations of LSD, psilocybin, DMT and SciSparc’s Palmitoylethanolamide (PEA), the active ingredient in SciSparc’s proprietary CannAmide. Initially filed as provisional patent applications with the U.S. Patent and Trademark Office, these applications build on the partnership, bringing the total number of joint patent submissions to 11, Clearmind said in a news release.

The recent patent applications contribute to Clearmind’s intellectual property protection, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, the company said. Notably, nine patents have been granted in major jurisdictions such as the US, Europe, China and India.